By Tomas J. Philipson
April 12, 2024
In their April 9 op-ed, “Big Pharma’s high prices don’t drive innovation,” Avik Roy and Gregg Girvan argued that Medicare’s new authority to demand lower prices from drug manufacturers will not result in the development and approval of fewer new drugs. Because most biotech innovation comes from smaller firms, they wrote, reducing revenue to Big Pharma will have minimal impact on drug creation.
Read the full article here.